(Philadelphia, PA) - Josep Dalmau, MD, PhD, has been named Associate Professor in the Department of Neurology at the University of Pennsylvania School of Medicine.

Prior to his appointment at Penn, Dr. Dalmau held faculty positions at the University of Arkansas for Medical Sciences, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, and University Autonoma of Barcelona in Spain. After earning his MD and PhD, with honors, from the Autonoma University of Barcelona School of Medicine, Dr. Dalmau completed a Residency in Neurology at the University Hospital de la Sta. Cruz y San Pablo, also in Spain, and fellowship training in Neuro-Oncology at Memorial Sloan-Kettering in New York.

Dr. Dalmau and his wife, Dr. Myrna Rosenfeld, were recruited to Penn to develop the Division of Neuro-Oncology to care for patients with malignant brain tumors and patients with systemic cancer with develop neurologic problems. They work closely with the Departments of Neurosurgery, Radiation Oncology, and Medical Oncology and will be holding clinical trials to test novel therapies for malignant brain tumors. The Division of Neuro-Oncology will offer clinical and research fellowship training in Neuro-Oncology. To compliment their clinical activities, Dr. Dalmau directs a National Institutes of Health (NIH)-supported research lab that studies neurologic autoimmune disorders that occur in patients with cancer called paraneoplastic neurologic diseases.

Among his many professional medical affiliations, he is an active member of the American Neurological Association, the American Academy of Neurology, the American Society of Clinical Oncology, American Association for Cancer Research, and the Society of Neuro-oncology. In addition to funding by the NIH, he has received several grants and awards including the Charles A. Dana Neuroscience Research Program Award and a Clinical Oncology Career Development Award from the American Cancer Society. Dr. Dalmau has contributed to many medical textbooks and has had his research published in journals including the New England Journal of Medicine, Journal of Clinical Oncology, Brain Pathology, Annals of Neurology, Brain, and Cell.

# # #


Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.

The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.